Imidapril - Wikipedia
Imidapril, sold under the brand name Tanatril among others, is an ACE inhibitor used as an antihypertensive drug and for the treatment of chronic heart failure. [1] It was patented in 1982 and approved for medical use in 1993. [2]
Imidapril: Uses, Interactions, Mechanism of Action | DrugBank ...
2016年10月20日 · Imidapril is an ACE inhibitor used in the treatment of essential hypertension. Generic Name Imidapril DrugBank Accession Number DB11783 Background. Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant. Type Small Molecule Groups Investigational Structure
Imidapril : Indications, Uses, Dosage, Drugs Interactions ...
2022年10月16日 · Imidapril, a prodrug of imidaprilat, is a competitive ACE inhibitor that prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor responsible for arterial vasoconstriction, increased blood pressure, and stimulation of aldosterone secretion.
Imidapril - Indications, Dosage, Side Effects and Precautions
2024年11月8日 · Imidapril(Hipertene) generic is an ACE inhibitor, prescribed for high blood pressure. It prevents the formation of angiotensin II through that it decreases blood pressure.
Tanatril. Imidapril for high blood pressure - Patient
2022年10月26日 · Imidapril belongs to a class of medicines called angiotensin-converting enzyme (ACE) inhibitors. You will have been prescribed it to reduce high blood pressure, a condition called hypertension. ACE inhibitors like imidapril prevent your body from creating a hormone known as angiotensin II.
Imidapril: a review of its use in essential hypertension ...
Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensiv …
Imidapril - an overview | ScienceDirect Topics
Numerous methods have proven effective in controlling the metabolic switch between glycolysis and OXYPHOS. RAAS inhibitors, like ACEIs and ARBs, are established treatments for DKD. Srivastava et al. showed that imidapril, an ACEI, suppressed glycolysis-mediated abnormal glucose metabolism and restored mitochondrial fatty acid oxidation. In ...
- 某些结果已被删除